Marinus Pharma (MRNS) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. TSCO
9. BE
10. SLM

Go back to Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 21, 2022 7:15 AM EDT

Received FDA approval of ZTALMY® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder; first approved treatment for this rare form of genetic epilepsy Awarded a Rare Pediatric Disease Priority Review Voucher by the FDA Eligible for an additional $30 million of funding under the existing Oaktree Capital Management, L.P. credit agreement Patient screening commenced for Phase 3 TrustTSC trial in tuberous sclerosis complex Resupply of clinical trial materials has been moved up to May 2022 for Phase 3 RAISE trial in refractory status epilepticus Marinus to... More